C. Duguet

A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01-02 study.

B. Grosbois, I. Yakoub-Agha, J. Mary, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

C. Brun-Buisson, J. Roujeau, P. Wolkenstein, 1998, The Lancet.

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.

P. Bouche, R. Gherardi, J. Revuz, 2002, The Journal of investigative dermatology.

Thalidomide in patients with advanced multiple myeloma.

B. Grosbois, I. Yakoub-Agha, S. Leyvraz, 2000, The hematology journal : the official journal of the European Haematology Association.

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

B. Grosbois, I. Yakoub-Agha, A. Duhamel, 2002, The hematology journal : the official journal of the European Haematology Association.

Thalidomide decreases the production of GM-CSF and TNF-α in the mixed epidermal cell-lymphocyte reaction

M. Bagot, J. Revuz, D. Charue, 1996 .

O95 Treatment of advanced multiple myeloma (MM) with thalidomide (THAL). Long term follow-up in a prospective study of 121 patients

B. Pégourié, P. Muret, B. Grosbois, 2003 .